Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Common Equity (2016 - 2025)

Historic Common Equity for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $52.9 million.

  • Protalix BioTherapeutics' Common Equity rose 6311.0% to $52.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.9 million, marking a year-over-year increase of 6311.0%. This contributed to the annual value of $43.2 million for FY2024, which is 2872.29% up from last year.
  • As of Q3 2025, Protalix BioTherapeutics' Common Equity stood at $52.9 million, which was up 6311.0% from $49.9 million recorded in Q2 2025.
  • Protalix BioTherapeutics' Common Equity's 5-year high stood at $52.9 million during Q3 2025, with a 5-year trough of -$11.5 million in Q3 2022.
  • Moreover, its 5-year median value for Common Equity was $28.6 million (2024), whereas its average is $19.3 million.
  • As far as peak fluctuations go, Protalix BioTherapeutics' Common Equity plummeted by 550563.38% in 2022, and later skyrocketed by 285496.03% in 2024.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Common Equity stood at -$6.0 million in 2021, then plummeted by 76.28% to -$10.6 million in 2022, then soared by 415.5% to $33.6 million in 2023, then grew by 28.72% to $43.2 million in 2024, then increased by 22.44% to $52.9 million in 2025.
  • Its Common Equity was $52.9 million in Q3 2025, compared to $49.9 million in Q2 2025 and $45.2 million in Q1 2025.